Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma

Table 2 Predictive factors for response of hepatic arterial infusion chemotherapy in patients with hepatocellular carcinoma

Variable	Univariable analysis		Multivariable analysis
	OR (95%CI)	P value	OR (95%CI)	P value
Age > 65 yr	2.61 (0.905–7.5)	0.076
Sex (male vs female)	0.853 (0.268–2.72)	0.788
Albumin > 2.8 g/dL	1.40 (0.404–4.85)	0.596
Prothrombin time > 80%	2.68 (1.010–7.10)	0.0469	1.98 (0.654–5.96)	0.227
Total bilirubin > 2 mg/dL	0.896 (0.317–2.53)	0.836
Platelet count > 20 × 104/µL	1.57 (0.268–9.16)	0.618
AFP > 50 ng/mL	0.523 (0.194–1.41)	0.199
DCP > 20 mAU/mL	0.381 (0.0938–1.55)	0.177
AFP-L3% > 20%	1.33 (0.491–3.62)	0.572
VEGF > 100 pg/mL	0.223 (0.0802–0.618)	0.0039	0.370 (0.127–1.07)	0.0677
Maximum tumor size > 2.3 cm	0.414 (0.130–1.32)	0.137
Tumor number > 2	1.07 (0.261–4.35)	0.928
Vascular invasion (present/absent)	1.73 (0.665–4.51)	0.261
ADAMTS13:AC > 75%	1.25 (0.355–4.41)	0.727
VWF:Ag > 260%	0.711 (0.279–1.81)	0.476
VWF:Ag/ADAMTS13:AC > 2.7	0.141 (0.0418–0.476)	0.0016	0.176 (0.0493–0.631)	0.00766

OR: Odds ratio; CI: Confidence interval; AFP: Alpha-fetoprotein; DCP: Des-γ-carboxy prothrombin; AFP-L3%: Lens culinaris agglutinin-reactive alpha-fetoprotein; VEGF: Vascular endothelial growth factor; ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: Ratio of VWF:Ag to ADAMTS13:AC.